Sandoz Stays Shut Out On Combigan In US Until 2022

 
• By Aidan Fry
  
Generate a summary of this article
Listen to this article
Beta

A US district court was right to bar Sandoz launching a generic version of Allergan’s Combigan glaucoma treatment due to limiting safety and efficacy clauses in three patents, the US Court of Appeals has confirmed.

Eye drops
Sandoz will likely have to wait until 2022 before bringing a generic of Combigan eye drops to the US market • Source: Shutterstock

Sandoz will be unable to launch a generic alternative to Allergan’s Combigan (brimonidine tartrate/timolol maleate) 0.2%/0.5% eye drops in the US for the next two-and-a-half years. The US Court of Appeals for the Federal Circuit has affirmed a New Jersey district court’s decision last year that Sandoz’ abbreviated new drug application infringed three valid patents, each protecting the glaucoma treatment through to 19 April 2022.

The Federal Circuit has upheld a preliminary injunction granted against Sandoz by the New Jersey district court, which found that...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Legal & IP

ADHD

This is regarding ADHD.

GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

 
• By Nabil

In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

MPP Finds Three More Partners On Key Hepatitis C Treatment

 
• By Akriti Seth

The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

 
• By David Wallace

Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.